OGN · Organon & Co.
$13.71
+0.01 (+0.07%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jul 31, 2026
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Market Cap
$3.61B
Shares
262.61M
Volume · Oct 1
2.1M
Avg daily vol (3M)
2.7M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.71
Open$13.71
Day$13.71–13.74
52W close$5.70–13.78
Avg vol 30d2.8M
Short int17.5M · 6.7% float · 5.5d
Short vol71%
Last earningsApr 30, 2026
DataMay 2021–Oct 2026
Filing10-Q · Jul 31
Up next
filed Jul 31, 2026
call held Feb 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.13B
Trailing 12 months
Net income (TTM)
$209.00M
Trailing 12 months
Revenue growth YoY
-2.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
17.6
Trailing earnings · reciprocal yield 5.7%
FCF yield
15.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$7.42B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.0%
Year over year · more shares
Price change (1Y)
+28.3%
Trailing year
Short interest
6.7%
Latest settlement · 5.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+0%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
99%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+55%
trailing
YTD return
+91%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow
Flat
1 of 646 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$200.3K over 90 days · 100% sells
Short interest
Rising
6.68% of float · ▲ +5.0% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
646 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
53%
contracting
EPS growth
−78%
Y/Y
Free cash flow
$538.0M
Valuation
P/E 17.6
below peers
Balance sheet
$8.1B
net debt
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
0.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Feb 12, 2026
Full Year 2026
Revenue
Initiated
$6.2B
prior FY $6.22B
midpoint −0.3% Y/Y
Adjusted EBITDA (non-GAAP)
Non-GAAP
Initiated
$1.9B
FY 2026
Interest
Non-GAAP
Initiated
$500M
Depreciation
Non-GAAP
Initiated
$140M
Guided vs delivered
· last 3 settled
Revenues
full-year 2024
guided $6.25B – $6.45B
$6.4B
In line
Revenues
Full Year 2023
guided $6.15B – $6.25B
$6.26B
Beat +1.0%
Full-year revenue guidance
full year 2021
guided $6.1B – $6.4B
$6.3B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
99%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow
Flat
1 of 646 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$200.3K over 90 days · 100% sells
Short interest
Rising
6.68% of float · ▲ +5.0% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
646 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $14 · 99%
Range high $14
vs 200-day avg +26%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGN
this stock
Organon & Co.
|
$3.61B | +91.2% | -2.9% | 17.6 | 6.7% |
|
LLY
ELI LILLY & Co
|
$1.11T | +7.0% | +44.7% | 39.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$653.61B | +25.0% | +6.0% | 31.5 | 0.9% |
|
ABBV
AbbVie Inc.
|
$466.80B | +13.8% | +8.6% | 74.6 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$367.07B | +36.6% | +1.3% | 119.0 | 1.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGN | -0.1% | -0.4% | +55.3% | +0.1% | +91.2% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +0.4% | -0.3% | +42.8% | -0.1% | +79.2% |
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
22 filings
14 filers
Visit website
Investor relations